Triazavirin is a guanine nucleotide analog antiviral first developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain. It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications. Given the similarities between SARS-CoV-2 and H5N1, health officials are investigating Triazavirin as an option to combat SARS-CoV-2, the coronavirus responsible for COVID-19. Its therapeutic use is listed as antivirals. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Triazavirin, 7-(methylsulfanyl)-3-nitro-1H, 4H-(1, 2, 4)triazolo(3, 2-c)(1, 2 and 4)triazin-4-one. Its PubChem CID is 3113817.
Riamilovir
| CAS No | 123606-06-4 |
|---|---|
| Molecular Formula | C5H4N6O3S |
| Molecular Weight | 228.19 g/mol |
| Synonyms | 7-methylsulfanyl-3-nitro-6H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Triazavirin is a guanine nucleotide analog antiviral first developed in Russia that has shown efficacy against influenza A and B, including the H5N1 strain. It appears that Triazavirin has shown promise in reducing influenza disease severity and associated complications.
The listed CAS number is 123606-06-4.
The listed molecular formula is C5H4N6O3S.
The listed molecular weight is 228.19 g/mol.
7-methylsulfanyl-3-nitro-6H-[1,2,4]triazolo[5,1-c][1,2,4]triazin-4-one.
The source lists Triazavirin, 7-(methylsulfanyl)-3-nitro-1H, 4H-(1, 2, 4)triazolo(3, 2-c)(1, 2 and 4)triazin-4-one.